Angela Mathison, PhD

Publications

• Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis.

  (Martin-Mateos R, De Assuncao TM, Arab JP, Jalan-Sakrikar N, Yaqoob U, Greuter T, Verma VK, Mathison AJ, Cao S, Lomberk G, Mathurin P, Urrutia R, Huebert RC, Shah VH.) Cell Mol Gastroenterol Hepatol. 2019;7(1):197-209.

• Mechanisms Underlying the Regulation of HP1γ by the NGF-PKA Signaling Pathway.

  (Seo S, Mathison A, Grzenda A, Podratz J, Calvo E, Brimijoin S, Windebank A, Iovanna J, Lomberk G, Urrutia R.) Sci Rep. 2018 Oct 10;8(1):15077.

• Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes.

  (Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, Armenoult L, Ayadi M, Ordog T, Lee JH, Oliver G, Klee E, Moutardier V, Gayet O, Bian B, Duconseil P, Gilabert M, Bigonnet M, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Secq V, De Reyniès A, Dusetti N, Iovanna J, Urrutia R.) Nat Commun. 2018 05 17;9(1):1978.

• Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe.

  (Mathison A, Salmonson A, Missfeldt M, Bintz J, Williams M, Kossak S, Nair A, de Assuncao TM, Christensen T, Buttar N, Iovanna J, Huebert R, Lomberk G.) Mol Cancer Res. 2017 08;15(8):984-997.

• Functional validation reveals the novel missense V419L variant in associated with Loeys-Dietz syndrome (LDS) impairs canonical TGF-β signaling.

  (Cousin MA, Zimmermann MT, Mathison AJ, Blackburn PR, Boczek NJ, Oliver GR, Lomberk GA, Urrutia RA, Deyle DR, Klee EW.) Cold Spring Harb Mol Case Stud. 2017 07;3(4).

• The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).

  (Sarmento OF, Svingen PA, Xiong Y, Sun Z, Bamidele AO, Mathison AJ, Smyrk TC, Nair AA, Gonzalez MM, Sagstetter MR, Baheti S, McGovern DP, Friton JJ, Papadakis KA, Gautam G, Xavier RJ, Urrutia RA, Faubion WA.) J Biol Chem. 2017 Jan 13;292(2):706-722.

• Asymmetric Cancer Hallmarks in Breast Tumors on Different Sides of the Body.

  (Campoy EM, Laurito SR, Branham MT, Urrutia G, Mathison A, Gago F, Orozco J, Urrutia R, Mayorga LS, Roqué M.) PLoS One. 2016;11(7):e0157416.

• Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.

  (Guo Y, Fan Y, Zhang J, Lomberk GA, Zhou Z, Sun L, Mathison AJ, Garcia-Barrio MT, Zhang J, Zeng L, Li L, Pennathur S, Willer CJ, Rader DJ, Urrutia R, Chen YE.) J Clin Invest. 2015 Oct 01;125(10):3819-30.

• Phenotypic Characterization of Mice Carrying Homozygous Deletion of KLF11, a Gene in Which Mutations Cause Human Neonatal and MODY VII Diabetes.

  (Mathison A, Escande C, Calvo E, Seo S, White T, Salmonson A, Faubion WA Jr, Buttar N, Iovanna J, Lomberk G, Chini EN, Urrutia R.) Endocrinology. 2015 Oct;156(10):3581-95.

• The Aurora A-HP1γ pathway regulates gene expression and mitosis in cells from the sperm lineage.

  (Leonard PH, Grzenda A, Mathison A, Morbeck DE, Fredrickson JR, de Assuncao TM, Christensen T, Salisbury J, Calvo E, Iovanna J, Coddington CC, Urrutia R, Lomberk G.) BMC Dev Biol. 2015 May 29;15:23.

• Browning of human adipocytes requires KLF11 and reprogramming of PPARγ superenhancers.

  (Loft A, Forss I, Siersbæk MS, Schmidt SF, Larsen AS, Madsen JG, Pisani DF, Nielsen R, Aagaard MM, Mathison A, Neville MJ, Urrutia R, Karpe F, Amri EZ, Mandrup S.) Genes Dev. 2015 Jan 01;29(1):7-22.

• Deleted in Breast Cancer 1 regulates cellular senescence during obesity.

  (Escande C, Nin V, Pirtskhalava T, Chini CC, Thereza Barbosa M, Mathison A, Urrutia R, Tchkonia T, Kirkland JL, Chini EN.) Aging Cell. 2014 Oct;13(5):951-3.